Erudio Healtherudio.com
Congress · Sep 12–15, 2026 · past meeting
IASLC 2026 World Conference on Lung Cancer
Trials whose public commentary places their results at IASLC 2026 World Conference on Lung Cancer, Sep 12–15, 2026. A trial is listed only when at least two public sources, from two publishers, place its results or presentation at the meeting; each row says how many did.
24 trials: 6 with reports and 18 with no report yet. Organised by International Association for the Study of Lung Cancer (IASLC); Erudio is not affiliated with it.
Focused$750Standard$1,250Deep$1,950Pricing
Reports: each is priced by its size, licensed permanently for your organization's internal use, with MCP access for your AI agent. Buy on the report's page. Team and enterprise access
Published reports · 6
What clinicians said about each trial in public, every statement linked to its source. Counts: verified statements, and how many of them come from speakers whose clinical role the NPI registry or their institution's staff page confirms.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Mesothelioma · 2 | |||||||
| CHIMERA pembrolizumab plus pemetrexed plus platinum-based chemotherapy placed at IASLC 2026 World Conference on Lung Cancer by 2 sources NCT06155279 · Istituto Oncologico Veneto IRCCS | resectable epithelioid and biphasic pleural mesothelioma | Phase 2 | 22 | 6 | Focused | Oct 31, 2026 | Preview |
| MiST rucaparib; abemaciclib; pembrolizumab plus bemcentinib placed at IASLC 2026 World Conference on Lung Cancer by 2 sources NCT03654833 · University of Leicester | relapsed malignant mesothelioma | Phase 2 | 227 | 35 | Focused | Nov 1, 2026 | Preview |
| Non-small cell lung cancer · 3 | |||||||
| SOLARA BH-30643; BH-30643 plus carboplatin plus pemetrexed placed at IASLC 2026 World Conference on Lung Cancer by 6 sources NCT06706076 · BlossomHill Therapeutics | EGFR- or HER2-mutated advanced NSCLC | Phase 1/Phase 2 | 71 | 23 | Focused | Oct 29, 2026 | Preview |
| DUMAS nivolumab plus carboplatin plus paclitaxel placed at IASLC 2026 World Conference on Lung Cancer by 3 sources NCT05684276 · Fundación GECP | NSCLC diagnosed with Pancoast tumor | Phase 2 | 17 | 8 | Focused | Oct 30, 2026 | Preview |
| ARTEMIDE-01 rilvegostomig placed at IASLC 2026 World Conference on Lung Cancer by 2 sources NCT04995523 · AstraZeneca | advanced or metastatic NSCLC | Phase 1/Phase 2 | 53 | 15 | Focused | Oct 29, 2026 | Preview |
| Small cell lung cancer · 1 | |||||||
| DeLLphi-309 tarlatamab placed at IASLC 2026 World Conference on Lung Cancer by 10 sources NCT06745323 · Amgen | small cell lung cancer | Phase 2 | 206 | 39 | Standard | Oct 27, 2026 | Preview |
No report yet · 18
Trial pages with the registry record and the public commentary we have indexed so far. The report is built on order from the trial page. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Non-small cell lung cancer · 12 | |||||||
| ADAURA osimertinib placed at IASLC 2026 World Conference on Lung Cancer by 36 sources NCT02511106 · AstraZeneca DeepView → | EGFR mutation-positive stage IB-IIIA non-small cell lung cancer | Phase 3 | Deep | View | |||
| PAPILLON amivantamab placed at IASLC 2026 World Conference on Lung Cancer by 31 sources NCT04538664 · Janssen Research & Development, LLC DeepView → | first-line EGFR exon 20 insertion-mutated advanced NSCLC | Phase 3 | Deep | View | |||
| DESTINY-Lung04 trastuzumab deruxtecan placed at IASLC 2026 World Conference on Lung Cancer by 23 sources NCT05048797 · AstraZeneca DeepView → | first-line HER2 exon 19/20-mutated advanced non-squamous NSCLC | Phase 3 | Deep | View | |||
| MDT-BRIDGE durvalumab plus platinum-based chemotherapy placed at IASLC 2026 World Conference on Lung Cancer by 10 sources NCT05925530 · AstraZeneca DeepView → | resectable or borderline resectable stage IIB–IIIB NSCLC | Phase 2 | Deep | View | |||
| HARMONi ivonescimab placed at IASLC 2026 World Conference on Lung Cancer by 8 sources NCT06396065 · Summit Therapeutics DeepView → | EGFR-mutant advanced non-squamous NSCLC after EGFR-TKI progression | Phase 3 | Deep | View | |||
| REZILIENT3 zipalertinib placed at IASLC 2026 World Conference on Lung Cancer by 7 sources NCT05973773 · Taiho Oncology, Inc. StandardView → | untreated EGFR exon 20 insertion-mutated advanced nonsquamous NSCLC | Phase 3 | Standard | View | |||
| EVOKE-03 sacituzumab govitecan plus pembrolizumab placed at IASLC 2026 World Conference on Lung Cancer by 6 sources NCT05609968 · Merck Sharp & Dohme LLC DeepView → | first-line PD-L1 TPS ≥50% metastatic non-small-cell lung cancer | Phase 3 | Deep | View | |||
| NAUTIKA1 alectinib; entrectinib; pralsetinib placed at IASLC 2026 World Conference on Lung Cancer by 6 sources NCT04302025 · Genentech, Inc. DeepView → | biomarker-selected resectable stages IB-III NSCLC | Phase 2 | Deep | View | |||
| AMIGO-1 amivantamab plus lazertinib plus pemetrexed placed at IASLC 2026 World Conference on Lung Cancer by 3 sources NCT05299125 · Latin American Cooperative Oncology Group DeepView → | first-line EGFR-mutated metastatic non-small cell lung cancer | Phase 2 | Deep | View | |||
| PRESERVE-003 gotistobart placed at IASLC 2026 World Conference on Lung Cancer by 3 sources NCT05671510 · OncoC4, Inc. DeepView → | metastatic squamous NSCLC after PD-(L)1 progression | Phase 3 | Deep | View | |||
| SOHO-01 sevabertinib (BAY 2927088) placed at IASLC 2026 World Conference on Lung Cancer by 3 sources NCT05099172 · Bayer DeepView → | advanced EGFR- and/or HER2-mutant non-small cell lung cancer | Phase 1/Phase 2 | Deep | View | |||
| EMPOWER-Lung 1 cemiplimab placed at IASLC 2026 World Conference on Lung Cancer by 2 sources NCT03088540 · Regeneron Pharmaceuticals DeepView → | first-line advanced NSCLC with PD-L1 expression ≥50% | Phase 3 | Deep | View | |||
| Small cell lung cancer · 4 | |||||||
| TAISHAN-302 tambotatug pelitecan (YL201) placed at IASLC 2026 World Conference on Lung Cancer by 19 sources NCT06612151 · MediLink Therapeutics (Suzhou) Co., Ltd. DeepView → | relapsed small cell lung cancer | Phase 3 | Deep | View | |||
| ARTEMIS-008 risvutatug rezetecan (HS-20093) placed at IASLC 2026 World Conference on Lung Cancer by 16 sources NCT06498479 · Hansoh BioMedical R&D Company DeepView → | relapsed small cell lung cancer | Phase 3 | Deep | View | |||
| MAVERICK Tests a strategy, not a drug placed at IASLC 2026 World Conference on Lung Cancer by 13 sources NCT04155034 · SWOG Cancer Research Network DeepView → | small cell lung cancer | Phase 3 | Deep | View | |||
| NCT05680922 LB2102 placed at IASLC 2026 World Conference on Lung Cancer by 2 sources NCT05680922 · Legend Biotech USA Inc FocusedView → | extensive stage small cell lung cancer | Phase 1 | Focused | View | |||
| Other · 2 | |||||||
| Beamion LUNG-1 zongertinib placed at IASLC 2026 World Conference on Lung Cancer by 4 sources NCT04886804 · Boehringer Ingelheim DeepView → | advanced or metastatic solid tumors with HER2 aberrations | Phase 1 | Deep | View | |||
| ARROS-1 zidesamtinib (NVL-520) placed at IASLC 2026 World Conference on Lung Cancer by 2 sources NCT05118789 · Nuvalent Inc. StandardView → | Not given | Phase 1/Phase 2 | Standard | View | |||